The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...

Two-time state champion golfer Frances Brown signed with Auburn Wednesday as part of National Signing Day 2025.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Each Soliqua 100/33 pen contains 3 milliliters (mL) of solution, with 300 units of insulin and 99 micrograms ... your doctor will determine the best treatment for it. They may prescribe a ...

Semaglutide is probably the best known of the new GLP-1 agonists ... or 1.8mg doses, while Saxenda pens also deliver higher doses of 2.4mg and 3mg. Xultophy is a combination of insulin and liraglutide ...

Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

When you're buying income stocks, a company's underlying business is arguably still the most crucial factor to consider, even more than the dividend yield. Corporations with high yields may look ...